In adults hospitalized with COVID-19, adding...

In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.

Abstract

SOURCE CITATION: Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888-99. 35617986.

Authors

Tran A; Rochwerg B

Journal

Annals of Internal Medicine, Vol. 175, No. 10,

Publisher

American College of Physicians

Publication Date

October 1, 2022

DOI

10.7326/j22-0074

ISSN

1056-8751

Associated Experts

Bram Rochwerg

Associate Professor, Faculty of Health Sciences

Visit profile

Labels